Abivax (NASDAQ:ABVX) Price Target Lowered to $151.00 at Truist Financial

Key Points

• Truist Financial lowered Abivax’s price target to $151 from $155 but maintained a “buy” rating, implying approximately 49% upside from the previous close.
• Wall Street remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $156.69; ratings include 13 Buys, one Strong Buy, one Hold, and one Sell.
• Abivax reported a larger-than-expected quarterly loss of $1.71 per share, though revenue of $1.37 million exceeded estimates. Analysts expect the clinical-stage biotechnology company to post a full-year loss of $3.22 per share.

Abivax (NASDAQ:ABVX - Get Free Report) had its target price reduced by research analysts at Truist Financial from $155.00 to $151.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Truist Financial's target price suggests a potential upside of 49.31% from the company's previous close.

A number of other brokerages have also issued reports on ABVX. HC Wainwright reiterated a "buy" rating on shares of Abivax in a report on Tuesday, June 30th. Citizens Jmp restated a "market outperform" rating and issued a $187.00 price target on shares of Abivax in a research report on Wednesday, July 1st. Jefferies Financial Group raised shares of Abivax from a "hold" rating to a "buy" rating and raised their price target for the company from $108.00 to $158.00 in a research note on Tuesday, June 30th. Barclays reiterated an "overweight" rating and set a $148.00 price target on shares of Abivax in a report on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Abivax in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Abivax currently has a consensus rating of "Moderate Buy" and a consensus target price of $156.69.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $101.14 on Tuesday. Abivax has a one year low of $69.81 and a one year high of $148.83. The company has a market cap of $8.83 billion, a price-to-earnings ratio of -19.50 and a beta of 0.96. The firm has a 50 day simple moving average of $120.76 and a 200 day simple moving average of $117.67.

Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, analysts expect that Abivax will post -3.22 EPS for the current year.

Hedge Funds Weigh In On Abivax

Institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP acquired a new stake in shares of Abivax during the 2nd quarter worth approximately $284,000. Readystate Asset Management LP boosted its stake in Abivax by 19.6% during the second quarter. Readystate Asset Management LP now owns 241,530 shares of the company's stock worth $32,186,000 after acquiring an additional 39,508 shares in the last quarter. Troluce Capital Advisors LLC bought a new position in Abivax during the second quarter worth $133,000. Seven Fleet Capital Management LP grew its holdings in Abivax by 158.6% in the second quarter. Seven Fleet Capital Management LP now owns 111,334 shares of the company's stock worth $14,836,000 after purchasing an additional 68,282 shares during the period. Finally, FNY Investment Advisers LLC increased its stake in Abivax by 7.3% in the second quarter. FNY Investment Advisers LLC now owns 7,605 shares of the company's stock valued at $1,013,000 after purchasing an additional 519 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

Key Abivax News

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax said it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. The company also reported €402.4 million in cash, cash equivalents and short-term investments at June 30, plus €767.1 million in net proceeds from its early-July offering, extending its cash runway into the fourth quarter of 2029. Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
• Positive Sentiment: The completed buyback of royalty certificates materially reduces a potential royalty overhang and leaves Abivax debt-free, improving financial flexibility ahead of possible commercialization. The company also appointed Tim Kelly as chief technical officer to support manufacturing, quality and commercial-supply readiness. Abivax Presents Business Updates and First Half 2026 Financial Results
• Neutral Sentiment: Analysts maintain an average “Moderate Buy” rating, suggesting that Wall Street remains constructive on the company’s longer-term prospects, although the stock’s roughly $9 billion valuation depends heavily on the success and regulatory progress of obefazimod. Abivax Receives Average Rating of Moderate Buy
• Neutral Sentiment: Chris Rabbat will succeed Fabio Cataldi as chief medical officer. The leadership transition may support continued clinical and regulatory execution, but it also introduces an additional management change as Abivax approaches key development milestones. Abivax Announces Chief Medical Officer Succession
• Negative Sentiment: Abivax reported a quarterly loss of $1.71 per share, substantially worse than the $0.92 consensus estimate. Although quarterly revenue of $1.37 million exceeded the $0.80 million forecast, the wider-than-expected loss and continued clinical-stage cash burn are weighing on sentiment. Abivax Releases Earnings Results and Misses EPS Expectations

Abivax Company Profile

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.